Manufacturers provide Phase 2b/3 Study data for aviptadil for reducing hospital stay among patients with respiratory failure due to critical COVID-19

Preliminary findings from an RCT (n=203) showed critical care COVID-19 patients with respiratory failure treated with maximal standard of care plus aviptadil had a shorter hospital stay compared to placebo.

Biospace Inc.